2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.14 Impact of Immune-Related Adverse Event Severity on Overall Survival in Patients Receiving PD-1/L1 Therapy, with a Focus on Combination Regimens

EP.11A.14 Impact of Immune-Related Adverse Event Severity on Overall Survival in Patients Receiving PD-1/L1 Therapy, with a Focus on Combination Regimens

Back to course

Pdf Summary

The study evaluates the impact of immune-related adverse events (irAEs) severity on the overall survival (OS) of patients receiving PD-1/L1 therapies for advanced non-small cell lung cancer (NSCLC), particularly in combination regimens. Conducted by the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, this research indicates a correlation between mild irAEs and improved patient outcomes across all immunotherapy regimens analyzed.<br /><br />Patients were categorized into those exhibiting severe, mild, or no irAEs, corresponding to toxicity grades established by the CTCAE 5.0 guidelines. The study covered a cohort treated between 2018 and 2022, using PD-1/L1 inhibitors either alone, with chemotherapy (IOCT), or in combination with CTLA-4 inhibitors (IOIOCT). Kaplan-Meier analysis was utilized to assess overall survival across these groups.<br /><br />Key findings suggest that mild irAEs are associated with longer OS in all treatment regimens compared to patients who did not experience irAEs. Conversely, while those with severe irAEs showed prolonged OS in single-agent immunotherapy, they exhibited shorter OS when treated with combination regimens (IOCT and IOIOCT).<br /><br />Specifically, irAE onset and frequency varied across regimens, with pneumonitis more common in single-agent and IOCT regimens, whereas dermatitis and colitis were prevalent in IOIOCT regimens. The study underscores the necessity of cautious monitoring of severe irAEs, particularly under combination therapies, to optimize the therapeutic benefit of immunosuppressive strategies. Overall, it highlights a crucial link between irAE severity and patient outcomes, advocating for balanced approaches in managing irAEs during immune-oncology treatments.

Asset Subtitle

Mayu Sugai

Meta Tag

Speaker Mayu Sugai

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immune-related adverse events

overall survival

PD-1/L1 therapies

non-small cell lung cancer

immunotherapy regimens

CTCAE 5.0 guidelines

Kaplan-Meier analysis

pneumonitis

dermatitis

colitis